Table 1. Amino acid changes in Gag-protease at time of treatment failure relative to pre-PI Gag-Protease sequence in study participants.
| Mutations at Treatment Failure, not present at the Pre-PI Timepoint | ||
|---|---|---|
| Patient | Gag | Protease |
| 1 | R26K, G387S | - |
| 2 | L46I, R91G, A95K, T109A, S111F, N124S, S239T, R268K | V13I |
| 3 | V34I | I77V |
| 4 | L34I, A37P, D42E, Q59M, K69R, L90E, T122A, N389I, Q468E, V469I, P473S, T487A | I13V, V72I |
| 5 | K26R, R30Q, E62A, T72S, Y79F, A81T, V82T, H89Q, R91Q, I94V, N124S, K127T, T138A, M142W, T144H, V147L, V215I, S252G, T332S, K335R, T339A, R406K, A431V*, P453L, L462I, G466R, S472F, N479S, E482D | I54V*, R57K, P63L, I84V* |
| 6 | V7I, G49D, R69Q, A120D, Q127K, N375S, I462S | - |
| 7 | S38G, A67T, N127K, K361R, P473A | - |
*I54V and I84V were not present in the same viral clone, but were present on separate clones. A431V developed only in the clones with I54V. ‘-‘) denotes when no changes in protease were present at failure.